Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
about
Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnosticsRigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.
P2860
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Real-time nanoscale proteomic ...... sponse to treatment of cancer.
@en
type
label
Real-time nanoscale proteomic ...... sponse to treatment of cancer.
@en
prefLabel
Real-time nanoscale proteomic ...... sponse to treatment of cancer.
@en
P2093
P2860
P1476
Real-time nanoscale proteomic ...... sponse to treatment of cancer.
@en
P2093
Alice C Fan
Dave R Praharaj
Dean W Felsher
Jennifer J O'Rourke
P2860
P304
P356
10.1517/13543784.2013.829453
P407
P577
2013-08-12T00:00:00Z